Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial

Simple item page
dc.contributor.authorRoberts, Sarah T.
dc.contributor.authorNair, Gonasagrie
dc.contributor.authorBaeten, Jared M.
dc.contributor.authorPalanee‑Philips, Thesla
dc.contributor.authorSchwartz, Katie
dc.contributor.authorReddy, Krishnaveni
dc.contributor.authorKabwigu, Samuel
dc.contributor.authorMatovu Kiweewa, Flavia
dc.contributor.authorGovender, Vaneshree
dc.contributor.authorGaffoor, Zakir
dc.contributor.authorSingh, Nishanta
dc.contributor.authorSiva, Samantha
dc.contributor.authorNaidoo, Kalendri
dc.contributor.authorMontgomery, Elizabeth T.
dc.date.accessioned2022-01-22T06:26:19Z
dc.date.available2022-01-22T06:26:19Z
dc.date.issued2020
dc.description.abstractidentified as one of the most significant factors impacting women’s willingness and ability to use them. As a result, research teams have sought to increase male partner involvement by encouraging disclosure of product use to male partners, promoting male partner engagement in the study through attendance at the study clinic, and helping women to garner male partner support for product use. This paper aims to assess the impact of these three elements of male partner involvement on women’s adherence to the dapivirine vaginal ring during MTN-020/ASPIRE, a phase III randomized placebo-controlled clinical trial involving 2629 women in Malawi, South Africa, Uganda, and Zimbabwe. During the study, 64–80% of participants reported disclosure of ring use at each quarterly visit, and 13% reported that their partners had attended the study clinic at some point during the study. At study exit, 66% reported that their partner was supportive, 18% unsupportive, and 17% were unsure. After adjusting for age, site and time in study, women were more likely to have low ring adherence if they had an unsupportive male partner (aRR 1.29, 95% CI 1.03–1.62). Neither disclosure nor clinic attendance directly predicted ring adherence, but disclosure increased the probability of having a supportive partner (aRRR 24.17, 95% CI 16.38–35.66) or an unsupportive partner (aRRR 4.10, 95% CI 2.70–6.24), relative to an unknown level of partner support. Women were also more likely to have a supportive partner if their partner had attended the clinic (aRRR 3.77, 95% CI 1.36–10.42). This study suggests that although the vaginal ring is relatively discreet, lack of support from male partners remains a relevant barrier to use. Though both disclosure and clinic attendance may increase partner support, disclosure may also increase partner opposition. Interventions to reduce male partner opposition are needed to maximize the potential impact of the ring and other PrEP products for HIV prevention.en_US
dc.identifier.citationRoberts, S. T., Nair, G., Baeten, J. M., Palanee-Philips, T., Schwartz, K., Reddy, K., ... & Montgomery, E. T. (2020). Impact of male partner involvement on women’s adherence to the dapivirine vaginal ring during a phase III HIV prevention trial. AIDS and Behavior, 24(5), 1432-1442. https://doi.org/10.1007/s10461-019-02707-1en_US
dc.identifier.urihttps://doi.org/10.1007/s10461-019-02707-1
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1419
dc.language.isoenen_US
dc.publisherAIDS and Behavioren_US
dc.subjectHIV preventionen_US
dc.subjectWomenen_US
dc.subjectMale involvementen_US
dc.subjectGenderen_US
dc.subjectDapivirine vaginal ringen_US
dc.titleImpact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Impact of Male Partner Involvement on Women’s Adherence.pdf
Size:
692.64 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences